Item |
Information |
Drug Groups
|
approved |
Description
|
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) |
Indication |
For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. |
Pharmacology |
Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. |
Affected Organisms |
• |
Humans and other mammals |
|
Half Life |
5-10 hours |
Elimination |
The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. |
Distribution |
* 7.5 ± 1.6 L |
Clearance |
* 1 L/h [IV administration] |
External Links |
|